Anti–Helicobacter pylori Treatment in Patients With Gastric Cancer After Radical Gastrectomy

In this cohort study of 1293 patients, the anti–H pylori treatment group had a significant survival advantage compared with the non–anti–H pylori treatment group in terms of overall survival and disease-free survival. After propensity score matching, the survival advantage for both overall and disease-free survival remained.